Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
SSY Group ( (HK:2005) ) just unveiled an update.
SSY Group Limited reported a challenging first half of 2025, with a significant decline in revenue and net profit due to a complex external environment and declining product prices. Despite these challenges, the company remains committed to its innovation-driven strategy, optimizing its product mix, and expanding market share. The company achieved notable success in centralized procurement projects, enhancing its regional market influence and facilitating market access for new products.
The most recent analyst rating on (HK:2005) stock is a Buy with a HK$3.50 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.
More about SSY Group
SSY Group Limited operates in the pharmaceutical industry, focusing on the production and distribution of intravenous infusion solutions, ampoule injections, bulk pharmaceuticals, oral preparations, and medical materials. The company is actively involved in national and local centralized procurement projects to enhance its market share and influence.
Average Trading Volume: 14,048,429
Technical Sentiment Signal: Sell
Current Market Cap: HK$8.97B
For an in-depth examination of 2005 stock, go to TipRanks’ Overview page.